BANGKOK DUSIT MEDICAL SERVICES FOREIGN R (OTCMKTS:BDULF) Reports Decline in Sellers; Strong Momentum for Longs

May 17, 2018 - By Tina Thibodeau

Bangkok Dusit Medical Services Public Company Limited (OTCMKTS:BDULF) Logo

The stock of BANGKOK DUSIT MEDICAL SERVICES FOREIGN R (OTCMKTS:BDULF) registered a decrease of 13.61% in short interest. BDULF’s total short interest was 30.36 million shares in May as published by FINRA. Its down 13.61% from 35.15M shares, reported previously. With 100 shares average volume, it will take short sellers 303648 days to cover their BDULF’s short positions. The short interest to BANGKOK DUSIT MEDICAL SERVICES FOREIGN R’s float is 0.39%.

It closed at $0.73 lastly. It is down 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Bangkok Dusit Medical Services Public Company Limited, together with its subsidiaries, operates hospitals in Thailand and internationally. The company has market cap of $11.47 billion. The firm owns and manages hospital groups, including Bangkok Hospital, Samitivej Hospital, BNH Hospital, Phyathai Hospital, Paolo Memorial Hospital, and Royal Hospital. It currently has negative earnings. It also operates longevity, neurological surgery, mental health rehabilitation and recovery, plastic surgery and reconstruction, neuroscience, civil aeromedical, skin and aesthetics, royal life anti-aging, health promotion, dental, trauma, referral, hyperbaric oxygen therapy, GI and Liver, rehabilitation, orthopedic, fracture, hip and knee, eye, LASIK, ear nose throat, womenÂ’s health, fertility, allergy asthma, chest and respiratory, urology, diabetes, thyroid, and endocrine centers, as well as hearing, speech, balance, and tinnitus center, as well as heart and cancer centers and clinics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: